









Markets
/
Stocks
/
nasdaq-pyxs
/

Pyxis Oncology Inc

PYXS

1.300USD

-0.089-6.44%

Market hours （ET）Quotes delayed by 15 min

42.57MMarket Cap

LossP/E TTM



Pyxis Oncology Inc

1.300

-0.089-6.44%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pyxis Oncology Inc

Currency: USD Updated: 2026-03-27

Key Insights

Pyxis Oncology Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 115 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.88.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pyxis Oncology Inc's Score

Industry at a Glance

Industry Ranking

115 / 391

Overall Ranking

231 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Pyxis Oncology Inc Highlights

StrengthsRisks

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Growing

The company is in a growing phase, with the latest annual income totaling USD 13.86M.

Fairly Valued

The company’s latest PE is -1.02, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 24.80M shares, decreasing 30.25% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 3.53K shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

6.875

Target Price

+394.60%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Pyxis Oncology Inc is 7.22, ranking 115 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.92

Change

0.3



Financials

5.64

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.13

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.76

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.58

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Pyxis Oncology Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Pyxis Oncology Inc is 7.24, ranking 141 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.02, which is -63.07% below the recent high of -0.38 and -337.78% above the recent low of -4.48.

Score

Industry at a Glance

Previous score

7.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 115/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Pyxis Oncology Inc is 8.89, ranking 40 out of 391 in the Biotechnology & Medical Research industry. The average price target is 7.70, with a high of 9.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

6.875

Target Price

+394.60%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Pyxis Oncology Inc

PYXS

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Pyxis Oncology Inc is 6.34, ranking 241 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.58 and the support level at 1.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.44

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.032

Sell

RSI(14)

38.858

Neutral

STOCH(KDJ)(9,3,3)

11.038

Oversold

ATR(14)

0.116

Low Volatility

CCI(14)

-156.231

Sell

Williams %R

92.857

Oversold

TRIX(12,20)

-0.069

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.382

Sell

MA10

1.474

Sell

MA20

1.477

Sell

MA50

1.500

Sell

MA100

2.409

Sell

MA200

2.113

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Pyxis Oncology Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 39.83%, representing a quarter-over-quarter increase of 19.35%. The largest institutional shareholder is The Vanguard, holding a total of 2.34M shares, representing 3.75% of shares outstanding, with 5.18% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Pfizer Inc

7.03M

Laurion Capital Management LP

3.63M

GordonMD Global Investments LP

3.83M

Bayer World Investments BV

2.74M

The Vanguard Group, Inc.

Star Investors

2.16M

+0.68%

Sullivan (Lara S. M.D.)

1.87M

-22.35%

Connealy (Pamela Ann)

1.20M

+126.66%

Palo Alto Investors LP

1.04M

683 Capital Management LLC

525.00K

-3.67%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pyxis Oncology Inc is 1.47, ranking 306 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.